NCT02082054 - StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Rhinitis, Seasonal, Allergic

Interventions

DRUG

PSE 120 mg, CM 8 mg, Atr 0.36 mg

"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"

DRUG

PSE 120 mg, CM 8 mg, Atr 0.24 mg

"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"

DRUG

PSE 120 mg, CM 8 mg, Atr 0.12 mg

"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"

DRUG

PSE 120 mg, CM 8 mg

Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID

DRUG

Atropine 0.24 mg

"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"

Trial Locations (4)

National Allergy, Asthma & Urticaria Centers of Charleston, PA, Charleston

Clinical Research Atlanta, Stockbridge

Family Allergy and Asthma Institute, Louisville

Central Texas Health Research, New Braunfels